A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

By El-Rayes Basil   Zalupski Mark   Shields Anthony   Ferris Ann   Vaishampayan Ulka   Heilbrun Lance   Venkatramanamoorthy Raghu   Adsay Volkan   Philip Philip  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 583-590

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer

By El-Rayes Bassel   Philip Philip   Sarkar Fazlul   Shields Anthony   Ferris Ann   Hess Kenneth   Kaseb Ahmad   Javle Milind   Varadhachary Gauri   Wolff Robert   Abbruzzese James  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 694-699

Springer Publishing Company

Access to resources Recommend Favorite

Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer: A Phase II Study

By Aristides Polyzos  

Clinical Drug Investigation, Vol. 24, Iss. 11, 2004-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

By Richter Suzanne   Bedard Philippe   Chen Eric   Clarke Blaise   Tran Ben   Hotte Sebastien   Stathis Anastasios   Hirte Hal   Razak Albiruni   Reedijk Michael   Chen Zhuo   Cohen Brenda   Zhang Wen-Jiang   Wang Lisa   Ivy S.   Moore Malcolm   Oza Amit   Siu Lillian   McWhirter Elaine  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 243-249

Springer Publishing Company

Access to resources Recommend Favorite